Efficacy and Safety Outcomes Among Treatment-Experienced Women and Men Treated with Etravirine in Gender, Race and Clinical ExperienceHODDER, Sally; JAYAWEERA, Dushyantha; MRUS, Joseph et al.AIDS research and human retroviruses. 2012, Vol 28, Num 6, pp 544-551, issn 0889-2229, 8 p.Article

CoFiDS: A Belief-Theoretic Approach for Automated Collaborative FilteringWICKRAMARATHNE, Thanuka L; PREMARATNE, Kamal; KUBAT, Miroslav et al.IEEE transactions on knowledge and data engineering. 2011, Vol 23, Num 2, pp 175-189, issn 1041-4347, 15 p.Article

Tipranavir : A ritonavir-boosted protease inhibitor. CommentaryCROOM, Katherine F; KEAM, Susan J; HICKS, Charles et al.Drugs (Basel). 2005, Vol 65, Num 12, pp 1669-1679, issn 0012-6667, 11 p.Article

Outcomes after orthotopic liver transplantation in 15 HIV-infected patientsSCHREIBMAN, Ian; GAYNOR, Jeffrey J; JAYAWEERA, Dushyantha et al.Transplantation. 2007, Vol 84, Num 6, pp 697-705, issn 0041-1337, 9 p.Article

Genotypic analysis of plasma HIV-1 RNA after influenza vaccination of patients with previously undetectable viral loadsKOLBER, Michael A; GABR, Abdel H; DE LA ROSA, Abel et al.AIDS (London). 2002, Vol 16, Num 4, pp 537-542, issn 0269-9370Article

Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96ARASTEH, Keikawus; YENI, Patrick; POZNIAK, Anton et al.Antiviral therapy (London). 2009, Vol 14, Num 6, pp 859-864, issn 1359-6535, 6 p.Article

Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients : 24-Week analysis from the RESIST-1 trialGATHE, Joseph; COOPER, David A; MUKWAYA, Geoffrey et al.Clinical infectious diseases. 2006, Vol 43, Num 10, pp 1337-1346, issn 1058-4838, 10 p.Article

Lopinavir/ritonavir maintenance monotherapy after successful viral suppression with standard highly active antiretroviral therapy in HIV-1-infected patientsCAMPO, Rafael E; LALANNE, Rose; TANNER, Thomas J et al.AIDS (London). 2005, Vol 19, Num 4, pp 447-449, issn 0269-9370, 3 p.Article

Safety of oral versus intravenous hydration during induction therapy with intravenous foscarnet in AIDS patients with cytomegalovirus infectionsCHEUNG, Tony W; JAYAWEERA, Dushyantha T; PEARCE, Daniel et al.International journal of STD & AIDS. 2000, Vol 11, Num 10, pp 640-647, issn 0956-4624Article

Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trialsNELSON, Mark; AMAYA, Gerardo; VANVEGGEL, Simon et al.Journal of antimicrobial chemotherapy (Print). 2012, Vol 67, Num 8, pp 2020-2028, issn 0305-7453, 9 p.Article

Human immunodeficiency virus type 1 pharmacogenomics in clinical practice: Relevance of HIV-1 Drug resistance testing (Part 1)PATARCA, Roberto; ISAVA, Alejandro; SCOTT, Gwendolyn et al.Journal of environmental pathology, toxicology and oncology. 2003, Vol 22, Num 3, pp 201-234, issn 0731-8898, 34 p.Article

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2 : a pooled subgroup analysis of data from two randomised trials. CommentaryMACARTHUR, Rodger D; CLOTET, Bonaventura; HAUBRICH, Richard et al.Lancet (British edition). 2007, Vol 369, Num 9568, issn 0140-6736, 1143-1144,1169-1178 [12 p.]Article

Human immunodeficiency virus type 1 pharmacogenomics in clinical practice: Relevance of HIV-1 Drug resistance testing (Part 2)PATARCA, Roberto; ISAVA, Alejandro; SCOTT, Gwendolyn et al.Journal of environmental pathology, toxicology and oncology. 2003, Vol 22, Num 4, pp 235-279, issn 0731-8898, 45 p.Article

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysisMILLS, Anthony M; NELSON, Mark; LAVREYS, Ludo et al.AIDS (London). 2009, Vol 23, Num 13, pp 1679-1688, issn 0269-9370, 10 p.Article

Gemini : A Noninferiority Study of Saquinavir/Ritonavir Versus Lopinavir/Ritonavir as Initial HIV-1 Therapy in AdultsWALMSLEY, Sharon; AVIHINGSANON, Anchalee; SCHUTZ, Malte et al.Journal of acquired immune deficiency syndromes (1999). 2009, Vol 50, Num 4, pp 367-374, issn 1525-4135, 8 p.Article

Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDSJACOBSON, Jeffrey M; HAFNER, Richard; REMINGTON, Jack et al.AIDS (London). 2001, Vol 15, Num 5, pp 583-589, issn 0269-9370Article

Quality of Life, Symptomatology and Healthcare Utilization in HIV/HCV Co-Infected Drug Users in MiamiBAUM, Marianna K; JAYAWEERA, Dushyantha T; RUI DUAN et al.Journal of addictive diseases. 2008, Vol 27, Num 2, pp 37-48, issn 1055-0887, 12 p.Article

Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients : 48-week results of a phase lib trialCOHEN, Calvin J; BERGER, Daniel S; MACK, Rebecca et al.AIDS (London). 2009, Vol 23, Num 3, pp 423-426, issn 0269-9370, 4 p.Article

Differences in the frequency of resistance to antiretroviral drug classes among human immunodeficiency virus type 1 clinical isolatesCAMPO, Rafael E; LICHTENBERGER, Paola N; ROSA, Isabella et al.Journal of clinical microbiology (Print). 2003, Vol 41, Num 7, pp 3376-3378, issn 0095-1137, 3 p.Article

Effect of class-specific therapy interruption on persistence of HIF type 1 antiretroviral resistanceCAMPO, Rafael E; ROSA, Isabella; LICHTENBERGER, Paola N et al.AIDS research and human retroviruses. 2003, Vol 19, Num 8, pp 653-656, issn 0889-2229, 4 p.Article

A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients : the MaxCmin2 trialDRAGSTED, Ulrik B; GERSTOFT, Jan; GAZZARD, Brian et al.Antiviral therapy (London). 2005, Vol 10, Num 6, pp 735-743, issn 1359-6535, 9 p.Article